CNS Involvement in Chronic Inflammatory Demyelinating Polyneuropathy
Subtle Retinal Changes in Optical Coherence Tomography
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received May 11, 2021
- Accepted in final form August 30, 2021
- First Published October 19, 2021.
Author Disclosures
- Jens Ingwersen, MD (jens.ingwersen{at}hhu.de),
- Jonas Graf, MD (jonas.graf{at}hhu.de),
- Julia Kluge (j.kluge{at}ymail.com),
- Margit Weise, PhD (margit.weise{at}med.uni-duesseldorf.de),
- Michael Dietrich, PhD (michael.dietrich{at}med.uni-duesseldorf.de),
- John-Ih Lee, MD (john-ih.lee{at}uni-duesseldorf.de),
- Jens Harmel, MD (jens.harmel{at}artemed.de),
- Hans-Peter Hartung, MD (hans-peter.hartung{at}uni-duesseldorf.de),
- Tobias Ruck, MD (tobias.ruck{at}med.uni-duesseldorf.de),
- Sven G. Meuth, MD, PhD (sven.meuth{at}uni-duesseldorf.de),
- Philipp Albrecht, MD (phil.albrecht{at}gmail.com),
- Orhan Aktas, MD (orhan.aktas{at}hhu.de) and
- Marius Ringelstein, MD
- Jens Ingwersen, MD (jens.ingwersen{at}hhu.de),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Jonas Graf, MD (jonas.graf{at}hhu.de),
NONE
NONE
JG received travel/meeting/accommodation reimbursements from Biogen, Merck Serono, Grifols, and Sanofi-Genzyme.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Research Fellowship from the Deutsche Forschungsgemeinschaft (project number 438899010)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Julia Kluge (j.kluge{at}ymail.com),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Margit Weise, PhD (margit.weise{at}med.uni-duesseldorf.de),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Performing of OCT-Imaging at Heinrich Heine University Duesseldorf
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Michael Dietrich, PhD (michael.dietrich{at}med.uni-duesseldorf.de),
NONE
NONE
(1) Merck, speaker honoraria
(1) Frontiers in Neurology, Review Editor, 2 years, (2) Frontiers in Immunology, Review Editor, 2 years.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Heinrich-Heine University
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- John-Ih Lee, MD (john-ih.lee{at}uni-duesseldorf.de),
(1) TEVA (2) Merz Pharma
NONE
(1) Merz, funding for travel to conference (2) TEVA, funding for travel to conference and for speaker honoraria (3) Allergan, funding for speaker honoraria (4) Ipsen, funding for speaker honoraria (5) Lilly, funding for speaker honoraria (6) Novartis, funding for speaker honoraria
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Merz
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Jens Harmel, MD (jens.harmel{at}artemed.de),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Hans-Peter Hartung, MD (hans-peter.hartung{at}uni-duesseldorf.de),
Novartis; Merck Serono; Teva; Biogen; Roche; Genzyme; BayerHealthcare; Sanofi; MedImmune; GeNeuro; Octapharma; BMS Celgene; Roche; CSL Behring; TG Therapeutics; Viela Bio /Horizon Therapeutics
NONE
Speaker Honoraria from: Biogen Genzyme Merck Novartis Roche
editorial board member (unpaid): CNS Drugs; Frontiers Neurology / Immunology; European Neurology; Journal of Clinical Medicine; Current Opinion in Neurology; Nature Reviews Neurology; Therapeutic Advances in Neurological Disorders; Journal of Neuroinflammation
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Tobias Ruck, MD (tobias.ruck{at}med.uni-duesseldorf.de),
TR has attended scientific advisory boards from Merck, Sanofi Aventis, Novartis, Alexion and Argenx.
NONE
TR has received honoraria from Celgene/BMS, Biogen, Roche, Sanofi Aventis, Alexion, Novartis, and Teva
Associate Editor for Frontiers in Neurology since 2019
NONE
NONE
NONE
NONE
NONE
NONE
NONE
TR has received research support from Merck, Novartis and Sanofi Aventis.
TR has reveived funding from the German research foundation and the Federal Ministry of Education and Research - BMBF.
NONE
TR has reveived funding from the Else Kröner Fresenius Foundation.
NONE
NONE
NONE
NONE
NONE
NONE
- Sven G. Meuth, MD, PhD (sven.meuth{at}uni-duesseldorf.de),
NONE
NONE
Sven G. Meuth received honoraria for lecturing and travel expenses for attending meetings from Almirall, Amicus Therapeutics Germany, Bayer Health Care, Biogen, Celgene, Diamed, Genzyme, MedDay Pharmaceuticals, Merck Serono, Novartis, Novo Nordisk, ONO Pharma, Roche, Sanofi- Aventis, Chugai Pharma, QuintilesIMS, and Teva.
NONE
Effectivity of specific FXII/FXIIa inhibitors, especially rHA-Infestin-4, in treating neuroinflammatory diseases (WO 2013/113774 A1 und EP 2 263 110 A1) Biomarkers for diagnosis and management of neuro- immunological diseases (WO 2016/028699 A2) NR2B selective NMDA-Receptor antagonists for treatment of immune-mediated inflammatory diseases (Reference number: PCT/EP2016/069975) Detection of anti-neurochondrin autoantibody in patients with cerebellar ataxia or cerebellitis (US10,112,982B2) Diagnosis of a novel autoimmune disease (EP086120B1; US2018/0298072,A1)
NONE
NONE
NONE
NONE
NONE
NONE
SGM's research is funded by Almirall, Amicus Therapeutics Germany, Biogen, Diamed, Fresenius Medical Care, Genzyme, Merck Serono, Novartis, ONO Pharma, Roche, and Teva
SGM's research is funded by the German Ministry for Education and Research (BMBF), Deutsche Forschungsgemeinschaft (DFG), German Academic Exchange Service, Interdisciplinary Center for Clinical Studies (IZKF) Muenster
NONE
SGM's research is funded by the German Foundation Neurology, Hertie Foundation, Else Kröner Fresenius Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Philipp Albrecht, MD (phil.albrecht{at}gmail.com),
(1) Novartis, serving on an advisory board; (2) Biogen, serving on an advisory board; (3) Ipsen, serving on an advisory board; (4) Merck, serving on an advisory board; (5) Merz, serving on an advisory board; (6) Roche, serving on an advisory board; (7) Allergan, serving on an advisory board; (8) Celgene, serving on an advisory board; (9) Janssen Cilag, serving on an advisory board;
NONE
(1) Novartis, travel/accommodation/meeting expenses and speaker honoraria; (2)Teva, travel/accommodation/meeting expenses and speaker honoraria; (3) Biogen, travel/accommodation/meeting expenses and speaker honoraria; (4) Merz Pharmaceuticals, travel/accommodation/meeting expenses, (5) Ipsen, travel/accommodation/meeting expenses; (6) Esai, travel/accommodation/meeting expenses; (7) Glaxo Smith Kline, travel/accommodation/meeting expenses; (8) Bayer Healthcare, speaker honoraria, travel/accommodation/meeting expenses; (9) Allergan, speaker honoraria, travel/accommodation/meeting expenses; (10) Celgene, travel/accommodation/meeting expenses; (11) (9) Merck, speaker honoraria, travel/accommodation/meeting expenses; (12) Bristol Meyers Squibb
(1) BMC Neuroscience, associate editor (2) Frontiers in Neurology, associate editor (3) Journal of Clinical Medicine, associate editor (4) Frontiers in Immunology, associate editor
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Biogen (2) Novartis (3) Merz Pharmaceuticals (4) Ipsen (5) Roche (6) Allergan (7) Celgene
European Fund For Regional Development (EFRE.NRW)
NONE
(1) Doktor Robert Pfleger Stiftung (2) Iselore Luckow Stiftung (3) Europäischer Fonds für Forschung und Regionale Entwicklung (EFRE)
NONE
NONE
NONE
NONE
NONE
NONE
- Orhan Aktas, MD (orhan.aktas{at}hhu.de) and
NONE
NONE
(1) Bayer, speaker honoraria (2) Novartis, speaker honoraria (3) Biogen, travel and speaker honoraria (4) Merck Serono, travel and speaker honoraria (5) Teva, speaker honoraria (6) Sanofi-Genzyme, speaker honoraria (7) Roche, travel and speaker honoraria (8) Almirall, speaker honoraria (9) Alexion, travel and speaker honoraria (10) Celgene, travel and speaker honoraria (11) Viela Bio, travel support
(1) PLoS ONE, Academic Editor, since 2012
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Novartis
(1) German Ministry of Science (BMBF), PI for NationNMO/KKNMS (NationNMO‐PAT FKZ 01GI1602B), since 2016
(1) German Research Foundation (DFG), PI in GRK2578, since 2020
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Marius Ringelstein, MD
1. Roche Pharma GmbH, served on a national scientific advisory board. 2. Alexion Pharma GmbH, served on a national scientific advisory board.
NONE
1. Alexion, speaking honorarium. 2. Roche,speaking honorarium and funding for travel to a conference. 3. Biogen Idec, funding for travel to a conference.
NONE
NONE
NONE
NONE
1. Roche Pharma GmbH, served on a national and international scientific advisory board. 2. Alexion Pharma GmbH, served on a national scientific advisory board.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Department of Neurology (J.A., J.G., J.K., M.W., M.D., J.-I.L., J.H., H.-P.H., T.R., S.G.M., P.A., O.A., M.R.), Medical Faculty, Heinrich-Heine-University Düsseldorf, Germany; Brain and Mind Centre (H.-P.H.), University of Sydney; Department of Neurology (H.-P.H.), Medical University of Vienna, Austria; Department of Neurology (H.-P.H., M.R.), Center for Neurology and Neuropsychiatry, LVR-Klinikum Düsseldorf, Germany; and Department of Neurology (H.-P.H.), Palacky University in Olomouc, Olomouc, Czech Republic.
- Correspondence
Dr. Ringelstein marius.ringelstein{at}med.uni-duesseldorf.de
Article usage
Letters: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Related Articles
- No related articles found.